Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Related Keywords

Jonathanb Zung , ,Company Fourth ,Nasdaq ,Roche Group ,Drug Administration ,Curis Inc ,Genentech ,Prnewswire Curis Inc ,Chief Development Officer ,Inducement Grant ,Fourth Amended ,Incentive Plan ,Aim Lymphoma ,Aim Leukemia ,Orphan Drug Designation ,Takeaim Leukemia ,Curis ,Nc ,Health Care Amp Hospitals ,Biotechnology ,Medical Pharmaceuticals ,